Cempra Pharmaceuticals, Inc.'s Solithromycin Demonstrates Safety and Tolerability in Patients With Chronic Liver Disease

Published: Sep 05, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHAPEL HILL, N.C., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that solithromycin demonstrated safety and tolerability in patients with mild to severe chronic liver disease. The pharmacokinetic analyses also showed that no dosage adjustments to compensate for decreased liver function were necessary in this patient population.

Help employers find you! Check out all the jobs and post your resume.

Back to news